Resources 
Product Resource
Learning
We Are Pleased to Announce: Global Commercial Licensing Rights for Jurkat E6.1, CHO-K1, and HEK293 Cell Lines Officially Secured.
ExploreArticles
NPFFR2: Dual Neural-Metabolic Target for Pain, Anxiety & Obesity — Drug Discovery & Cell Models
NPFFR2 is a powerful neuro-metabolic dual switch and a high-potential target for treating pain, anxiety, opioid addiction, and obesity. The 2025 Cell Reports structural breakthrough has opened a new era of structure-based rational drug design.To achieve efficient and reliable drug R&D, researchers require rigorously validated stable NPFFR2 cell models to support agonist screening, cAMP inhibition, EC50 quantification, and mechanistic studies. These tools bridge structural biology and drug development, accelerating hit compound discovery, strengthening candidate optimization, and promoting clinical translation.
BAFF/BAFFR Signaling: B-Cell Life-or-Death Switch & Drug Discovery Cell Models
BAFF/BAFFR is the defining key survival regulator for B cells and a cornerstone of immune drug discovery. Its well-validated clinical value and clear signaling mechanism make it a top target for autoimmune diseases and B-cell malignancies. To accelerate reliable and reproducible R&D, researchers need well-characterized, stable BAFF/BAFFR cell models that support functional assays, antibody screening, potency quantification, and mechanistic validation. These tools transform complex biological mechanisms into robust, quantitative, and actionable datasets, enabling faster candidate selection, stronger intellectual property, and smoother clinical translation.
CD3E: The T-Cell Activation Switch and Cell Models for Targeted Therapeutics
As the core switch for T-cell activation, CD3E is not only a fundamental key to understanding adaptive immunity, but also a crucial target in the development of immuno-oncology and autoimmune disease therapeutics. With the continuous iteration of bispecific antibody and CAR-T technologies, the demand for precise CD3E target-specificity evaluation tools has become increasingly urgent. ReqBio's newly launched CD3E KO NFAT-Luc Jurkat and CD3E KO Jurkat cell models—backed by well-defined genetic backgrounds and comprehensive functional validation—provide global drug developers with a highly accurate and efficient suite of assessment tools to accelerate next-generation therapies.
MRGPRX2: Mechanism, Therapeutics, and Cell Models
The rapid rise of MRGPRX2—from a relatively niche "itch receptor" to a star target in the development of drugs for allergic and inflammatory diseases—is the result of a profound convergence between fundamental immunology and clinical translational medicine. With the clinical advancement of programs like EP262 and EVO-756, the druggability of this target has already received preliminary validation. ReqBio remains committed to focusing on cutting-edge GPCR targets. By providing high-quality functional cell models and comprehensive assay services, we aim to empower the discovery and translation of innovative medicines for patients worldwide.
CHRM1-5 Subtypes: Structure, Mechanism, Drug Discovery, and Cell
The five subtypes, CHRM1–5, constitute the core network of cholinergic signaling. Their differentiated distribution and functions provide a rich array of targets for precision medical intervention. This field is currently witnessing a new surge in R&D—spanning from M1/M4 agonists for Alzheimer’s disease and M4-selective agonists for schizophrenia, to M3 antagonists for COPD and M1 antagonists for multiple sclerosis.
Orphan Receptor GPR84: The "Invisible Switch" Linking Metabolism and Inflammation
GPR84 is an orphan GPCR primarily expressed in immune cells that responds to medium-chain fatty acids (MCFAs) and regulates inflammation and metabolism, emerging as a novel target for diseases such as ulcerative colitis (UC), fibrosis, and NASH. This article systematically interprets the biological functions, signaling pathways, and clinical progress of GPR84, while highlighting the validation data and advantages of ReqBio’s GPR84/CHO and GPR84/β-Arrestin/CHO cell models—providing reliable tools for your early-stage drug R&D.
